Precision Medicine · global
Blood Testing Connects Patients to New Breast Cancer Therapy: FDA Approves Companion Diagnostic for Wilserdly
After advanced breast cancer develops treatment resistance, genetic changes in the tumor may offer clues for the next treatment. FoundationOne Liquid CDx has been approved to identify patients eligible for combination therapy with Wilserdly, but negative test results and long-term survival benefits each leave questions that require clarification.
When breast cancer is no longer controlled by the original endocrine therapy, the next treatment choice often depends on what has changed in the tumor. On November 16, the U.S. Food and Drug Administration (FDA) approved the liquid biopsy test FoundationOne Liquid CDx to identify breast cancer patients with ESR1 mutations who may be eligible for Wilserdly (generic name: giredestrant) in combination with everolimus, formally linking tumor genetic signals in the blood to the new therapy.
The FDA approved the drug combination on the same day for adults with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. Patients must have experienced recurrence during or after completing adjuvant endocrine therapy, or disease progression after at least one endocrine regimen for metastatic disease; the mutation must be confirmed by an FDA-authorized test. Foundation Medicine said this is the first companion diagnostic approved in the United States for use with this combination therapy.
ESR1 mutations serve as a basis for guiding treatment selection because they may contribute to tumor resistance to endocrine therapy. Giredestrant is an oral selective estrogen receptor degrader that acts on this signaling pathway, which drives breast cancer growth. Liquid biopsy looks for tumor alterations in cell-free DNA in the blood; in the evERA trial supporting this approval, researchers used FoundationOne Liquid CDx to focus their analysis on specific ESR1 ligand-binding domain mutations in circulating tumor DNA.
This phase III, randomized, open-label trial enrolled 373 patients, 207 of whom had tumors with ESR1 mutations. Roche stated that participants had previously received a CDK4/6 inhibitor and endocrine therapy. Both trial groups received everolimus, combined with either giredestrant or a physician-selected endocrine drug such as exemestane, fulvestrant, or tamoxifen. The trial therefore compared two combination treatment strategies.
In the ESR1-mutated population, median progression-free survival was 10 months in the giredestrant group and 5.5 months in the control group; the hazard ratio for disease progression or death was 0.38, corresponding to a 62% relative risk reduction. This finding supports a benefit in delaying disease progression, but it cannot be interpreted as a 62% increase in lifespan. The FDA noted that overall survival data were immature at the time of the progression-free survival analysis.
Treatment benefits must also be weighed alongside side effects. Common adverse reactions listed by the FDA include stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis, and nausea; the prescribing information also includes warnings for bradycardia and embryo-fetal toxicity. Oral administration makes treatment arrangements more convenient, while continued monitoring of tolerability and safety remains necessary.
The test itself also has limitations. Foundation Medicine cautioned that a negative liquid biopsy result does not rule out relevant alterations in the tumor; if the mutation required for the companion diagnostic is not detected, confirmation with an FDA-approved tumor tissue test should follow where feasible. This approval establishes a clear path from molecular testing to treatment for eligible patients; it does not guarantee that everyone will find a suitable drug, and it has yet to answer whether the combination can extend overall survival.